Results 71 to 80 of about 16,938 (228)

Thymectomy for myasthenia gravis [PDF]

Thorax, 1972
Between 1951 and 1971 thymectomy was performed on 41 patients with myasthenia gravis. They were selected from a total group of 95 myasthenic patients receiving anticholinesterase therapy. The criteria for selecting patients for thymectomy and the assessment of their progress after operation are described.
F R, Edwards, A, Wilson
openaire   +2 more sources

Impact of Prior Intravenous Immunoglobulin and Plasmapheresis on Eculizumab or Ravulizumab Treatment for Generalized Myasthenia Gravis: An Analysis of the MG SPOTLIGHT Registry

Clinical and Experimental Neuroimmunology, Volume 17, Issue 1, February 2026.
ABSTRACT Objective The complement component 5 inhibitor therapies (C5ITs) eculizumab and ravulizumab are approved for the treatment of generalized myasthenia gravis (gMG). We evaluated the real‐world effectiveness and safety of eculizumab and ravulizumab in patients with gMG with or without prior intravenous immunoglobulin (IVIg) or plasma exchange ...
Akiyuki Uzawa, Ema Rodrigues, Hiroyuki Murai   +2 more
wiley   +1 more source

Myasthenia. Surgical treatment and its effectiveness

Acta Biomedica Scientifica, 2012
The article reviews the problems of diagnostics and. treatment of myasthenia. The authors consider that thymectomy in modern conditions is founded, expedient and. safe for the patients surgery at the treatment of different forms of myasthenia.
M. B. Skvortsov, A. I. Smolin
doaj  

Descriptive analysis of therapeutic outcomes between thoracoscopic and transsternal thymectomy in myasthenia gravis patients from 2011 to 2021

Journal of Cardiothoracic Surgery
Background Myasthenia gravis is an autoimmune disease with high prevalence of thymus disorders, in which, thymectomy is considered one of the therapeutic approaches in improving the patients’ clinical outcomes.
Mahdiye Lashkarizadeh, Vahid Haghollahi, Nazanin Zeinali Nezhad, Mohammadreza Lashkarizadeh, Amirhossein Shahpar   +4 more
doaj   +1 more source

1‐Year Clinical Outcome Post‐Myasthenic Crisis: A Multicenter Prospective Study in China

European Journal of Neurology, Volume 33, Issue 2, February 2026.
In this prospective cohort of 282 patients with myasthenic crisis (MC) episodes, all‐cause mortality was 15.16%. Among 247 patients who have completed 1‐year follow‐up, 79.76% achieved favorable outcomes with significant improvement in the MG‐activities of daily living (MG‐ADL) score.
Xiao Huan, Ran Chen, Lei Jin, Yuan Wang, Yafang Xu, Lei Yang, Caihua Xi, Jianming Zheng, Lijun Luo, Song Yang, Jianquan Shi, Yanping Liu, Zhe Ruan, Wanlong Wu, Wei Li, Yaoxian Yue, Yarong Li, Wenji Jia, Huahua Zhong, Chong Yan, Jie Song, Jianying Xi, Song Tan, Qilong Jiang, Zhangyu Zou, Chongbo Zhao, Sushan Luo, on behalf of the Chinese Myasthenia Gravis Collaborating Group (CMGCG), Yuzhou Guan, Yuwei Da, Huan Yang, Ting Chang, Yuge Wang, Bitao Bu, Hongyu Zhou, Chunsheng Yang, Hua Zhang, Hui Deng, Ruisheng Duan   +38 more
wiley   +1 more source

Comparison of total parathyroidectomy without autotransplantation and without thymectomy versus total parathyroidectomy with autotransplantation and with thymectomy for secondary hyperparathyroidism: TOPAR PILOT-Trial [PDF]

, 2007
Background Secondary hyperparathyroidism (sHPT) is common in patients with chronic renal failure. Despite the initiation of new therapeutic agents, several patients will require parathyroidectomy (PTX).
Katja Schlosser, Johannes A Veit, Stefan Witte, Emilio Domínguez Fernández, Norbert Victor, Hans-Peter Knaebel, Christoph M Seiler, Matthias Rothmund, MM Salem, A Owda, F U, K/DOQI, J Silver, E Slatopolsky, E Slatopolsky, GA Block, S Ribeiro, WG Goodman, P Raggi, GA Block, CA Johnson, OS Indridason, HM Maung, M Wada, GA Block, EA Slatopolsky, E Slatopolsky, KJ Martin, KJ Martin, M Hirata, F Malberti, Y Tominaga, W Fassbinder, SW Stanbury, RE Wilson, ML Richards, M Rothmund, TB Drueke, P Kinnaert, S Ockert, K Lorenz, CS Ogg, S Stracke, ML Nicholson, H Hampl, KA Skinner, Y Tominaga, JF Henry, P Kinnaert, GM Hargrove, JR Bessell, RM Higgins, B Niederle, S Walgenbach, S Yumita, CA Patow, M Kaye, K Farrington, G Gasparri, RN Saunders, OH Clark, K Kaczirek, FN Pattou, GW Summers, K Schlosser, F Zaraca, S Walgenbach, RA Welk, FF Chou, C Dotzenrath, Z Korzets, M Kaye, H Hampl, D Ljutic   +73 more
core   +2 more sources

Thymic hyperplasia as a rare etiology of pure red cell aplasia: A case report [PDF]

Vojnosanitetski Pregled
Introduction. Thymic hyperplasia is a rare condition caused by an increase in cellular thymic mass and, in some cases, is associated with autoimmune diseases, such as pure red cell aplasia (PRCA).
Arsenović Isidora, Leković Danijela, Šefer Dijana, Pavlović Miroslav, Ivanović Jelena, Smiljanić Mihailo, Bogdanović Andrija   +6 more
doaj   +1 more source

Myasthenia Gravis With Acetylcholine Receptor Antibodies in the Very Old: Treatment Challenges and Diagnostic Pitfalls

European Journal of Neurology, Volume 33, Issue 2, February 2026.
Myasthenia gravis in the very old and with debut after age 65 years increases in incidence and prevalence. Early, active symptomatic and immunosuppressive treatment is needed with the aim of obtaining pharmacological remission or minimal manifestations only. Myasthenic crisis with respiratory failure remains a threat.
Nils Erik Gilhus
wiley   +1 more source

Add‐On Telitacicept Significantly Improves Outcome of Patients With Refractory Ocular Myasthenia Gravis a Real‐World Case Series

Brain and Behavior, Volume 16, Issue 1, January 2026.
6/7 patients achieved CMI by the third follow‐up, sustained to the fourth follow‐up, and 4/6 reached MSE by the fifth follow‐up. First real‐world evidence of adding telitacicept efficacy in refractory ocular MG symptoms Abstract Introduction Refractory ocular myasthenia gravis (MG) represents a significant therapeutic challenge, as conventional ...
Jing Lin, Yue Li, Mengcui Gui, Bitao Bu, Zhijun Li   +4 more
wiley   +1 more source

Steps in immunosuppression for renal transplantation [PDF]

, 1983
The authors provide a historical survey of the immunosuppressive agents that have been used to prevent allograft rejection.
Hakala, TR, Rosenthal, JT, Starzl, TE
core